Bivalent HPV Recombinant Vaccine (Cervarix) for the Prevention of Cervical Cancer

The bivalent human papillomavirus (HPV) recombinant vaccine (Cervarix) is the second vaccine to be approved in the US for the prevention of cervical cancer, cervical adenocarcinoma in situ, and cervical intraepithelial neoplasia caused by HPV types 16 and 18. Unlike the quadrivalent HPV vaccine (Gar...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	American family physician 2010-12, Vol.82 (12), p.57
Hauptverfasser:	Schauner, Stephanie, Lyon, Corey
Format:	Artikel
Sprache:	eng
Schlagworte:	Cervical cancer Disease prevention Effectiveness Human papillomavirus Safety Vaccines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!